Bayer Investors Face a Dual Catalyst: Earnings Data and Washington’s Glyphosate Ruling

Bayer enters a crucial week with Q1 earnings and a US Supreme Court case on glyphosate liability, testing its turnaround and legal exposure amid mixed stock performance.

Bayer enters what may be its most consequential week of the year so far. On Tuesday the group delivers first-quarter results, and across the Atlantic the US Supreme Court is weighing a case that could reshape the company’s legal exposure to glyphosate. The twin events have already injected a dose of caution into the stock, which closed Friday at €36.98 in Xetra trading.

The share price tells a story of short-term pain against a backdrop of long-term recovery. Over the past 30 days Bayer has shed 7.83%, and the monthly decline stands at 8.65%. Yet on a 12-month view, the stock has rallied 54.44%, with some calculations putting the gain closer to 57%. Technically, the picture is mixed: the equity now trades below its 50-day moving average but still above the 200-day line. A short signal from the MACD indicator on 7 May added to pre-report jitters, amplifying the stakes for Tuesday’s numbers.

That nervousness is understandable given the recent past. In the fourth quarter of 2025, Bayer booked a loss of €3.82 per share on revenue of €11.44 billion. For the full year 2026, analysts on average expect earnings of €4.25 per share, making the first-quarter update a critical check on whether the restructuring under CEO Bill Anderson is gaining traction. The focus will be on cash-flow quality and operational efficiency — two metrics that have been under particular scrutiny as the group juggles demands in both its pharma and crop-science divisions.

The legal overhang adds a separate layer of risk. Investors are watching the Supreme Court’s decision in the Durnell case, which concerns liability for the herbicide glyphosate. An adverse ruling would once again shine a spotlight on Bayer’s multi-billion-dollar litigation legacy and could complicate the narrative of a turnaround that is still in its early stages. While the timing of the court’s decision remains uncertain, the mere proximity of the announcement is enough to heighten volatility.

Against that uncertain backdrop, several large banks have maintained constructive ratings. UBS holds a “Buy”, while Barclays and JP Morgan stick with “Overweight”. The consensus is that the fundamental thesis — Bayer’s long-term position in health and agriculture — remains intact. But the market is looking for proof, not promises. Strong cash-flow figures and convincing evidence of cost-control progress could blunt the technical selling pressure, while a weak report would risk extending the recent slide. Tuesday’s disclosure is as much a referendum on execution as it is a snapshot of past performance.